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A Pilot Test of DNA-based Analysis 
Using Anonymized Newborn Screening 
Cards in Iowa 
M. Therese Lysaught, Lisa Milhollin, Ryan Peirce, 
Jane Getchell, William Rhead, Jan Susanin, Jeannette Anderson, 
and Jeffrey C. Murray 
Since the early 1960s, newborn screening programs for inborn errors of me-
tabolism have served as a standard component in routine neonatal health care 
in the United States and have played an important role in fostering child 
health. ) -3 Currently, roughly 4 million newborns are screened each year in the 
United States. From the beginning, these programs have evolved within and 
been conducted under the jurisdiction of the individual states.· Since these 
programs have been developed on a state-by-state basis, screening policies 
vary widely, both with regard to diseases screened for (anywhere from three 
to eleven conditions, including biotinidase deficiency, branched chain keto-
acidemia, congenital adrenal hyperplasia, congenital hypothyroidism, cysticfi-
brosis, galactosemia, homocystinuria, phenylketonuria, hemoglobinopathies, 
toxoplasmosis, and tyrosinemia) and with regard to regulatory policies.5 - 6 
The Iowa Neonatal Metabolic Screening Program (INMSP) is located with 
the agency of the University ofIowa Hygienic Laboratory (the Hygienic Lab), 
the state of Iowa's primary agency of public health analysis and information. 
The INMSP obtains blood samples in the form of blood-spotted filter-paper 
cards from each of the 37,000 - 40,000 babies born in Iowa each year and uses 
these to screen for five metabolic disorders: hypothyroidism, phenylketonuria 
(PKU), galactosemia, congenital adrenal hyperplasia (CAH), and hemoglo-
binopathies: Until recently, a sixth disorder, branched chain ketoacidemia, 
also known as "maple syrup urine disease" (MSUD), was also assayed, but 
MSUD screening was discontinued due to lack of cost effectiveness. Using 
different microbiological, biochemical, and radio-immuno assays, the INMSP 
detects roughly three dozen total cases of these disorders per year. In these 
cases, early detection and diagnosis leads to dietary and other interventions 
which, if followed carefully, can reduce or forestall the often catastrophic ef-
fects of these diseases, such as severe mental retardation or early death. 
We obtained newborn screening filter cards from the INMSP for a pilot 
project using DNA-based analysis. The purpose of this study was twofold. 
3 
First, we wanted to determine the suitability of using DNA-based techniques 
on these samples on a large scale as alternatives to the INMSP's microbiologi-
cal, biochemical, and radio-immuno assays. The above disorders can be de-
tected through various types of metabolic assays, since the immediate and 
severe effects of the disease are directly related to abnormally high levels of 
specific metabolic products. The etiologic cause of four of the five conditions, 
excepting hypothyroidism, are, however, genetic. Because of mutations in 
relevant genes, these individuals fail to produce a protein necessary for normal 
metabolism or produce a defective · form of a protein. Consequently, these 
conditions seem likely candidates for detection and diagnosis through DNA-
based analysis. Moreover, other disorders stemming from genetic mutations 
do not result in the types of metabolic changes that can be assayed through 
these techniques, but recent advances in human genetics have made direct 
detection of disease-causing DNA mutations possible.> In· some instances, 
again, early detection and treatment may improve ou~ome . However, one 
consideration for any newborn screening program or comprehensive popu-
lation screening study is the ability efficiently and accurately to process large · 
numbers of samples in a reasonably short period (quickly enough to initiate 
an efficacious therapeutic intervention). To move from metabolic assays to 
strictly DNA-based techniques would require that DNA-based assays could be 
performed under these constraints. 
As a second purpose of this study, we wished to ascertain the efficacy of . 
using these samples and DNA-based techniques for measuring various types 
of genetic variation in the Iowa population, where "genetic variation" encom-
passes both carrier frequencies for disease-related mutations and normal trait 
variation. As mentioned, the specimens for the INMSP are collected, trans-
ported, and analyzed via "Guthrie" or filter-paper cards. These Guthrie cards 
in general, when not discarded by states after the newborn screening assays 
are complete, have been described as "inchoate 'DNA banks.''' 8 - 9 Along these 
lines, it was recognized that these samples could provide a sort of genetic data-
bank for the Iowa population, which, after the development of an efficient 
technique for extracting DNA from the filter cards, could serve as a useful 
reference or control database for comparison in other genetic research or 
could provide important public health information. 
As with most developments in biomedicine and genetics, these projects -
though technical and data-oriented on their face - cannot be separated from 
the ethical issues that surround them. In particular, two sets of issues are 
raised. First, how would the introduction of DNA-based techniques alter the 
practice of newborn screening? What additional concerns or issues might 
these techniques introduce? What lacunae in current newborn screening prac-
4 : Clinical and Research Settings 
tices does the specter of these techniques illuminate? A second issue is that of 
"DNA databanking." Specifically, for our purposes, what issues arise when 
samples obtained from patients for one purpose (e.g., newborn screening) are 
then used for secondary purposes unrelated to the original intent (e.g., re-
search, forensic, diagnostic, or commercial purposes)? What different issues 
are presented by the uses of "anonymized" samples versus samples that retain 
identity linkages to the original patient? These questions are addressed in our 
discussion. 
First we describe our pilot test of DNA-based analysis using anonymized 
newborn screening cards in Iowa. After testing several methods for extracting 
DNA samples from the blood spots on the filter-paper cards, we carried out 
an analysis for three different disease-producing mutations: the cystic fibrosis 
(CF) .:lFso8 mutation, variations in exon 12 of the phenylalanine hydroxylase 
gene (mutations in which contribute to PKU), and variations in the gene 
responsible for MCADD (Medium Chain Acyl-CoA Dehydrogenase Defi-
ciency) . These genes represent three different classes of conditions relative to 
newborn screening programs: (1) PKU screening is currently conducted in 
all fifty states using traditional methods; (2) CF is screened for in two states 
using metabolic assays, with pilot programs for the addition of a DNA-based 
confirmation assay being tested in Wisconsin and internationally5, 10- 14; and 
(3) MCADD is not currently screened for in any state in the United States, 
Methods 
In 1989 the Hygienic Lab began participating in a study sponsored by the 
Centers for Disease Control (CDC) which sought to determine the prevalence 
of human immunodeficiency virus (HIV) infection in newborns,15-16 For this 
study, the Hygienic Lab utilized the newborn screening filter cards from the 
INMSP to determine HIV seroprevalence for the state of Iowa, Prior to being 
entered into the HIV study, the filter cards were rendered anonymous: name 
identifiers were removed, and each card was assigned a random number. Al-
though random, this number remained correlated with the INMSP database 
of demographic and clinical information created from the original sample. 
(For each sample tested, the INMSP enters into its database the sample num-
ber, the test results, and a set of demographic characteristics of the newborn.) 
Consequently, for each anonymous sample, important information has been 
preserved, but it is impossible to trace a particular sample back to a particular 
newborn. 
While in a number of states newborns' screening cards are retained for 
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different lengths of time and policies regarding their testing and subsequent 
usage vary,.· S in Iowa, once these samples were analyzed by both the INMSP 
and the Hygienic Lab/CDC HIV study, they would be destroyed. Prior to our 
study, this was done. Following review by both the Iowa State Board of Health 
and the Birth Defects Institute, we were able to obtain these samples for the 
purpose of this study. From July 1994 through May 1995, 31,249 newborn 
screening filter cards were obtained from the INMSP via the Hygienic Lab. 
DNA was extracted from 8,920 samples in 96-well microtiter plates. Using 
a Ys" punch, a l/S" blood-spot sample was punched from each newborn screen-
ing card directly into one well of the plate. (Spaces were left for positive and 
negative controls.) After autoclaving, extraction solution was added to the 
sample, the sample was processed, and the resulting supernatant was trans-
ferred, using a multichannel micropipet, to a fresh 96-well ~icrotiter plate in 
which the samples were frozen and stored. These plates also then served as 
templates for PCR analysis. We are in the process of d~veloping an optimal 
method for long-term storage of the blood-spot filter-paper cards.s 
A PCR-based protocol was developed, and we assayed 7,194 samples for the 
presence of the ~F508 mutation in the cystic fibrosis transmembrane con-
ductance regulator gene (CFTR), the common mutation accounting for ap-
proximately 70 percent of the incidence of cystic fibrosis. Cystic fibrosis is the 
most common severe autosomal recessive disorder affecting Caucasians of 
European descent, with an incidence of approximately 1 in 2,500 births. The 
CFTR ~F508 mutation is a three base-pair deletion which is easily detected on 
6 percent polyacrylamide gels. Control DNA was provided by Coriell. 
In addition, we developed a polymerase chain reaction (PCR)-based assay 
to detect mutations in exon 12 of the phenylalanine hydroxylase (PAH) gene 
and tested 1,070 samples. Different mutations in this gene when present in 
recessive fashion contribute to the disease phenylketonuria (PKU), which oc-
curs in approximately 1 in 12,000 births. Individuals with PKU lack the en-
zyme which metabolizes the amino acid phenylalanine; the resulting elevated 
phenylalanine levels can result in severe brain damage. Early intervention and 
a diet low in phenylalanine can prevent mental impairment. 
This assay detected three known mutations, R408W, Y 414C, and IVS12ntl, 
as well as two other variants. These variants all resulted from nucleotide sub-
stitutions rather than deletions or insertions and were therefore not detectable 
by polyacrylamide sequencing gels. Instead, these samples were analyzed us-
ing mutation detection electrophoresis (MDE) gel solution in a single strand 
conformational polymorphism (SSCP) protocol. To determine which signals 
corresponded with which variants, anonymous specimens from individuals 
known to have PKU were extracted, amplified through PCR, and analyzed on 
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MDE gels. The samples showing variations under the gel conditions were ex-
cised and sequenced. The sequence data enabled identification of the particu-
lar mutation. These samples then served as controls. 
We are now in the initial phases of testing for a mutation in the gene re-
sponsible for MCADD, an autosomal recessive disorder that has been associ-
ated with Sudden Infant Death Syndrome in a small percentage of SIDS cases. 
MCADD can also cause a disorder associated with mental retardation. Again, 
since presymptomatic diagnosis and dietary intervention can minimize symp-
toms and forestall life-threatening episodes, and there appears to be one com-
mon point mutation in Caucasian populations, MCADD is a natural candi-
date for this approach. A single mutation, T1067C, comprises about 85 percent . 
of known cases of MCADD, and we designed primers to amplify a 188-bp 
segment of DNA that includes this region. Fortuitously, it also flanks a A985G 
change that causes MCADD in a small group of cases. 
Results 
As noted above, DNA samples were prepared from 8,920 blood-spot filter-
paper cards. Of the 7,194 samples assayed for the CFTR ~F508 mutation, 6,659 
individuals did not carry the mutation, 177 individuals were heterozygous for 
the mutation, and 1 individual was homozygous; 357 samples did not produce 
an interpretable result (through failure to amplify or defects in the gels). 
The CF screening on neonatal cards from August 1994 to August 1995 
yielded the following results: 
. No. tested 
No. failures 
Carrier rate 
Allele frequency 
Heterozygotes (carriers) detected 
Homozygotes detected 
7,194 
375 (5.6%) 
1/38 
0.013 
177 
1 
The MCADD pilot DNA screening on neonatal cards (May 20,1996) had 
the following results: 
No. tested successfully 
No. of mutations 
A985G 
T1067C 
Carrier rate 
Predicted homozygotes in Iowa 
per year (40,000 births) 
857 
13 
11 
2 
1/67 
2 
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The results of the PKU screening on neonatal cards (July 9,1995) were as 
follows: 
No. tested 
No. of failures 
No. of variants 
1,070 
252 (23.5%) 
73 (6.8%) 
This results in a carrier frequency of 1: 38 for the CFTR LlF508 mutation in 
the Iowa population, which is similar to that reported in a study of the Wis-
consin population IO, ll as well as in other Caucasian populations. Although the 
overall sample failure rate for the CF portion of the pilot study was 5 percent, 
the rate improved over the course of the study as the protocol was optimized; 
for the last 2,460 samples, the rate dropped considerably, to 1.4 percent (35 out 
of 2,460). We hope that, with additional modifications of Qur current proto-
cols, the current sample failure rate will fall even further. 
Of the 1,070 samples assayed for the variants in exon l.? of the phenylalanine 
hydroxylase gene, 997 did not show evidence of a detectable mutation and 
73 individuals with variants were found. While these 73 variants comprise a 
large number of PKU mutations, the variability of our SSCP results makes it 
likely that most of these will be sequence polymorphisms and not etiologic 
mutations. 
An SSCP assay was used to screen 857 newborn screening samples for the 
MCADD mutations. Eleven individuals were heterozygous for T1067C and 
two for A985G. Thus, 1.5 percent of Iowa newborns are heterozygotes for 
MCADD, and we would predict 1 in 17,000 newborns (about 2 per year) to be 
homozygous affected. This assay could readily be carried out by a screening 
facility. 
While the first aim of this study was to develop and conduct DNA-based 
analyses on dried blood spots on a large scale, a second aim was to develop a 
databank of anonymous samples for control purposes and other genetic re-
search. As mentioned above, at the conclusion of this study, a sample bank of 
31,249 blood-spot filter-paper cards had been obtained; 8,920 of these were 
prepared as DNA samples with a volume of approximately 150 microliters. 
These DNA samples are frozen and stored in capped 96-well micro titer plates, 
providing for relatively easy storage, maintenance, and utilization. At the same 
time, the original source of each sample is maintained on the filter-paper 
cards, making verification or re-extraction relatively easy and ensuring that 
samples will remain available for subsequent research. This pool will provide 
an important resource for conducting comprehensive surveys of genetic varia-
tion in the Iowa population. 
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Discussion 
DNA-BASED ANALYSIS FOR NEWBORN S C REENING: 
T E CHNI C AL CONSIDERATIONS 
Through this study, we have developed a relatively efficient procedure for 
extracting DNA from large numbers of samples. As the protocol was opti-
mized, we were consistently able to extract DNA from over 98 percent of the 
samples. With all steps of the protocol- extraction, PCR, storage - con-
ducted in 96-well microtiter plates, we were able to process large numbers of 
samples relatively efficiently. Much of this process could be automated, in-
creasing effitiency. 
But even under manual conditions the efficiency of the DNA-based assay 
is comparable to that required for a newborn screening program. For ex-
ample, with a birth rate for the state ofIowa of approximately 37,000-40,000 
annually and 20 percent repeat specimen (see below), the INMSP processes 
an average of 900 samples per week, conducting six different metabolic assays 
on each specimen with a staff of six. In the DNA-based protocol we developed, 
it was relatively easy for one person to extract and PCR 1,600 samples per 
week. For the cystic fibrosis protocol, using the 6 percent polyacrylamide gels 
made the analysis relatively straightforward; because each gel could be loaded 
five or six times, it is feasible for one person to analyze the same 1,600 samples 
within the same time frame. The SSCP/MDE protocol for the PKU assay pre-
sented more challenges. Since it was not amenable to double-loading and the 
results of the SSCP procedure seemed more variable, it was not as efficient. 
Moreover, our results demonstrate that, to date, we have been able to assess 
accurately the frequency of the cystic fibrosis mutation in the state of Iowa, 
and we find that the frequency is similar to that identified in other predomi-
nantly Caucasian populations. Finally, although the results are preliminary, 
we did not observe evidence of contamination from filter-card to filter-card 
or evidence of cross-contamination between extracted and stored samples 
within the plates when handled carefully, even though the samples were pro-
cessed in close proximity. 
DNA-BASED. ANALYSIS FOR N E WBORN SC RE E NING: 
ETHI C AL CONSIDERATIONS 
If DNA-based techniques came to be used in place of traditional micro-
biological or biochemical assays, would it be a zero-sum exchange? Would it 
simply mean the substitution of one technical approach for another? Decid-
edly not. Because of the nature of genetic information and the current social 
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and cultural context into which DNA-based newborn screening would be in-
troduced, additional issues must be considered carefully to determine whether 
DNA-based techniques are appropriate for programs such as newborn screen-
ing, and, if so, under what conditions or parameters. These issues include 
advantages, cost, precision or diagnostic efficacy, scope of application, collat-
eral information, and informed consent. 
Advantages: Solution to Problem of Early Discharge 
and Mutation Identification 
DNA-based techniques would provide one primary advantage over current 
traditional methods. If technically feasible, DNA-based assays would offer a 
solution to what has become a significant problem for many state newborn 
screening programs, namely, the current practice of early di~charge of infants. 
In an effort to reduce health care costs, many insurance providers and HMOs 
either encourage or require that healthy infants be diicharged twenty-four 
hours after birth; some infants are being discharged as early as twelve hours. 
This has presented a problem for newborn screening programs insofar as 
many newborn screening tests rely on time-dependent changes in the concen-
tration of an analyte in the blood for diagnosis.5 If a sample is taken too early, 
the true concentration of these compounds in the infant's blood may be 
masked by maternal analytes, rendering false negative results. Until techno-
logical advances enable age-independent analyses, the INMSP will continue to 
request a second specimen on roughly 17 percent (or 7,800) of all babies tested 
annually. This results not only in increased costs; clearly, some of these babies 
will be missed. 
A second possible advantage of DNA-based techniques is that, in making 
the diagnosis, they not only would indicate that an infant suffered from a 
particular disease, but would often be able to specifically identify the mutation 
or mutations responsible for the disease-state. As genetic medicine becomes 
more sophisticated, this may render information relevant to diagnosis and 
treatment (e.g., some mutations may cause more severe symptoms than oth-
ers). However, it may be more efficient to reserve DNA-based assays for con-
firmatory tests on the small subs ample of newborns who are determined to 
be "presumptive positives" through metabolic assays. This approach is being 
tested in Wisconsin and elsewhere for cystic fibrosis .IO-14 
Cost and Diagnostic Efficacy 
While DNA-based techniques could resolve the problem offalse negatives 
due to early discharge and offer enhanced diagnostic precision in some cases, 
they would not necessarily result in reduced costs or reduced numbers of false 
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negatives. Currently, the metabolic screening assays used to detect PKU, galac-
tosemia, MSUD, CAH, hypothyroidism, and hemoglobinopathies are rela-
tively inexpensive and efficient.5 The INMSP currently charges $25.00 for the 
battery of five tests. The costs of a genetic assay are comparable, in the range 
of approximately $2.00 per assay, when one takes into consideration the costs 
of supplies and labor. 
But while the direct costs of the genetic assays are comparable to those for 
the metabolic assays, a difficulty arises in the area of precision or diagnostic 
accuracy due to the genetic nature of these diseases. Each condition can be 
caused by any number of mutations, each of which may require a different 
DNA-based assay. For example, over 100 disease-related mutations have been 
reported in the PAH gene. Our protocol assayed for a number of mutations in 
exon 12, a region of the gene which seems to be particularly susceptible to 
mutations and which is the location of some of the more frequent mutations. 
And while we detected variants in seventy-three individuals, the individual 
listed in the INMSP database as a "presumptive positive" for PKU based on 
the metabolic assay performed by the INMSP appeared as "normal" in our 
assay. Thus, to design an efficient protocol which would not give false-negative 
results would be quite difficult under the current technological conditions. A 
condition such as CF would be more amenable, since such a large proportion 
of the mutations occur at one locus; but again, although the ~F508 mutation 
accounts for approximately 70 percent of the cases of cystic fibrosis, approxi-
mately 400 other disease-causing mutations in the CFTR gene have also been 
identified. Likewise, while in MCADD 85 percent have a single mutation, 
other mutations can contribute to disease. 
But while a particular gene may be susceptible to a large number of muta-
tions (the PAH gene, for example) the metabolic disease-producing effects of 
different mutations are, in general, similar (elevated levels of the amino acid 
phenylalanine, which can be measured through a single assay which measures 
gene expression). Consequently, the current consensus holds that DNA-based 
assays are not yet sufficiently "cost-effective" and are susceptible to false nega-
tive results. The American Society of Human Genetics and others IH8 have ar-
gued on this basis that CF screening on a population-wide basis is premature at 
this time. Likewise, although a large number ofPKU mutations have been iden-
tified through this protocol, at the present time we conclude that current meth-
0dologies are more appropriate and cost -effective for carrying out this analysis. 
Scope of Application and Collateral Information 
The possibility of large-scale genetic screening next raises the question of 
the scope of conditions to which it could be applied. At issue in this question 
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is whether genetic information, obtained through DNA-based techniques, is 
different in kind from the sort of medical information obtained through tra-
ditional metabolic assays.19 Current metabolic techniques assay for single, 
well-defined conditions that result in active disease states. DNA-based assays 
would yield not only this information but what we could call "collateral infor-
mation" as well. 
Two types of collateral information can become available through genetic 
assays. A first type is information predictive of the infant's possible medical 
future. DNA-based assays could detect conditions of late onset presympto-
matically, possible predispositions to certain conditions, "behavioral" traits, 
or diseases for which no therapy exists. A second kind of collateral informa-
tion is heterozygosity or carrier status. These types of information are materi-
ally relevant not only to the individual newborn; both cate$ories divulge in-
formation about parents, siblings, and other relatives as well: that they may 
also be carriers or bearers of latent illness. Thus, not o!lly is the information 
detected through DNA-based assays different in kind; it is different in scope 
as well. 
Clearly, in the context of newborn screening programs, testing for these 
sorts of conditions differs little from the genetic testing of children in other 
contexts. Although far from resolved, the contentious debate surrounding the 
propriety of the genetic testing of children has recently begun moving toward 
a tentative resolution. The particulars of this debate as well as the outlines of . 
the emerging consensus can be found in the joint statement of the American 
Society of Human Genetics/American College of Medical Genetics 20 and an 
analysis by D. C. Wertz et alY 
Genetic tests for children can be separated into two basic categories: (1) tests 
that provide an immediate or timely medical benefit and (2) those that do not 
but might prove medically useful at a later time or might provide some sort of 
psychosocial benefit. Agreement is unanimous regarding the first category: 
testing that may detect conditions for which treatment or preventive measures 
are available is similar to other medical diagnostic evaluations and is not only 
ethically sound but mandated.20 - 21 
With regard to the second category of genetic tests on children - those 
that offer no immediate medical benefit - there is less unanimity, precisely 
because of the collateral information that is divulged by these tests and the 
risks of harm that it presents to both individual children and their families. 
Certainly, these sorts of tests provide certain benefits, as noted by the ASHG / 
ACMG: either increased or reduced medical surveillance (as appropriate); 
early intervention; preventive measures, including lifestyle changes; clarifica-
tion of diagnosis; reduction of anxiety and uncertainty; opportunity for psy-
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chological adjustment; ability to make realistic plans for education, employ-
ment, insurance, and personal relationships; alerting other relatives to genetic 
risk; and avoiding or preparing for the birth of a child with genetic disease.2o 
However, the current consensus holds that these sorts of benefits, when 
calculated in the context of individual testing, are greatly outweighed by the 
risks of harm presented by collateral information. These risks include alter-
ation of self-image (latent feelings of unworthiness, "survivor guilt," pessi-
mism about the future, blaming oneself for the illness and the burdens it 
places on the family); distortion of parents' perception of the child (mani-
fested possibly in the overindulging "vulnerable child syndrome," stigmatiza-
tion, or scapegoating and rejecting); lowered expectations by self, parents, and 
others for education, employment, and personal relationships; and alerting 
relatives to reproductive or health risksY-23 In addition, this sort of informa-
tion may generate rather than reduce anxiety. N. A. Holtzman notes that anxi-
ety generated by false positive results from neonatal assays is, at times, difficult 
to dispel, even with follow-up testing.24 Finally, as has been discussed at length 
elsewhere,2s-30 this sort of information presents the additional risk of illegiti-
mate access, in this era of increasing computerized and electronic datakeeping, 
by third parties (i.e., insurers, employers, educational institutions) with the 
attendant possibilities for discrimination. These types of discrimination can 
exacerbate and reinforce the social stigmatization and marginalization that of-
ten accompany chronic illness and "difference." 
Based on the scope of these risks, many persons find it difficult to justify 
subjecting children to genetic tests that provide no immediate medical benefit. 
The ASHG/ACMG recommends that "if the medical or psychosocial benefits 
of a genetic test will not accrue until adulthood, as in the case of carrier status 
or adult-onset diseases, genetic testing should generally be deferred." 20 Excep-
tions are made to take into account the emerging identity, cognitive ability, 
and self-determination of children, especially as they move through adoles-
cence. Consequently, the recommendations almost categorically oppose test-
ing children under the age of seven (understood as the age where children are 
beginning to be capable of "assent"); they allow for more flexibility and con-
textual decisionmaking as the age, maturity, and ability of the child to partici-
pate in the decision to be tested increase. 
Thus, when located in the context of the genetic testing of children, the 
issues of the scope of application of DNA-based assays in newborn screening 
and the management of collateral information seem relatively straightforward. 
Current newborn screening programs exemplify the first category mentioned 
above. Newborn screening programs have been developed within a framework 
of preventive therapeutic medicine guided by the two ethical principles of 
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preventing harm and providing benefit: the goal of these programs has been 
to identify affected infants prior to imminent development of symptoms 
where treatment is available in order to prevent serious morbidity or death.z> 
Harvey Levy has identified four traditional criteria that have governed new-
born screening programs: (1) that there be a disease, not simply a laboratory 
variation; (2) that the disease should cause significant problems; (3) that the 
problems caused by the disease be amenable to treatment directed at prevent-
ing symptoms; and (4) that a marker for the disease be identifiable in the 
newborn prior to the appearance of symptoms and irreversible damage." The 
use of well-defined DNA-based assays in newborn screening, guided by these 
criteria, would likely meet with widespread support. 
Likewise, it would probably be difficult to justify the implementation of 
DNA-based assays in a newborn screening context for diseases for which the 
benefit of early intervention is uncertain or no therapy exists, for presympto-
matic or susceptibility testing, or for carrier testing. ':'hile one could con-
ceivably extrapolate the benefits listed earlier to a public health context (e.g., 
presymptomatic testing could identify, far in advance of their symptoms, 
individuals who will develop specific disorders; this information could di-
rect prevention, surveillance, and early-intervention efforts toward those who 
need them most), the risks would likewise be extrapolated and, in a public 
health context, would be magnified exponentially. 
Current newborn screening programs have, of course, already wandered 
into some of this territory. For some conditions, DNA-based or traditional 
assays are relatively straightforward, but early medical or psychosocial inter-
vention is not known to affect outcome. Consensus has not been reached 
on this issue, for example, with regard to neonatal testing for cystic fibrosis, 
using either metabolic assays or a two-tiered (metabolic/DNA-based) ap-
proach.23 - 24, 3 1 Moreover, carrier status information already emerges from 
newborn screening technologies: identification of an affected child identifies 
both parents as carriers. The move toward DNA-based assays, however, would 
exacerbate this already difficult problem by introducing a new variable into 
the outcome of newborn screening tests: DNA-based tests would, like cur-
rent tests for hemoglobinopathies, detect not just disease incidence but het-
erozygosity as well. If the stated and enacted purpose of newborn screening 
programs is the diagnosis and treatment of early-onset disease; how might 
information on heterozygosity be handled? If heterozygosity for a recessive 
condition is detected in an infant, it might seem prud~nt - and guided by 
the same preventive therapeutic goals as newborn screening - to counsel the 
parents for both to be tested, to determine the disease risk for future offspring. 
This has, in fact, come to be understood by some as a secondary goal of new-
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born screening programs.22 - 23 Is there an obligation to make carrier status for 
a particular disease (e.g., PKU) available to identified infants, either as part of 
their medical record or when they reach reproductive age? 
The Committee on Assessing Genetic Risks of the Institute of Medicine, in 
its 1994 report Assessing Genetic Risks, addressed both of these issues. First, 
with regard to the scope of application, it articulated three principles that 
should guide the development of newborn screening programs, namely, that 
there is: (1) clear benefit to the newborn; (2) a system in place to confirm the 
diagnosis; and (3) treatment and follow-up available for affected newborns 
regardless of families' ability to pay.32 This would disqualify presymptomatic 
or susceptibility screening; the Council of Regional Networks of Genetic Ser-
vices (CORN) concurs.33 The committee further recommends that the devel-
opment of new population-based newborn screening programs be viewed as 
research protocols and be conducted under established guidelines for human 
subjects research, requiring informed consent and well-designed and peer-
reviewed pilot studies that demonstrate safety, effectiveness, and clear benefit 
to the newborn prior to implementation. Finally, they counsel that carrier 
status information (and by analogy, other sorts of collateral information) on 
newborns should be withheld from either or both parents in the absence of 
a specific request for the information. This accords with the findings of the 
ASHG/ACMG and others. We affirm these guidelines and recommend that 
the development of newborn screening programs be limited to those with 
demonstrable clinical outcomes. This conclusion derives both from a sense of 
the purpose and practice of medicine, of which genetics is a part, and from a 
sense of stewardship of community resources. 
Informed Consent in Newborn Screening 
The ability of parents to request possible carrier status findings requires 
that they be informed in advance that such information will be available; this 
requires that they know that a sample has been obtained from their child and 
that such a test is going to be performed, which is not often the case. This 
brings us to the role of informed consent in newborn screening. Like many 
other facets of newborn screening, the role of informed consent has evolved 
in an ad hoc manner, and policies vary widely from state to state. Currently, 
forty-eight states and the District of Columbia have statutes regulating new-
born screening. Delaware and Vermont conduct screening on a voluntary ba-
sis but have not regulated these programs by statute. In three jurisdictions 
(District of Columbia, Maryland, and North Carolina) screening is entirely 
voluntary, while in five (Arkansas, Iowa, Michigan, Montana, and West Vir-
ginia) it is mandatory; the rest legally permit parents to "opt-out." 4 
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The extent to which parents are informed of this option, however, is un-
clear. Lori Andrews' 1985 study of state newborn screening programs found 
that only thirteen states require or specify that parents be informed that neo-
natal screening tests are even going to be performed; only four of these states 
require that parents be given an opportunity to object. In thirty-two addi-
tional states, Andrews found there to be no requirement for informing parents 
that the tests are to be conducted, for obtaining their consent, or for apprising 
them of their right to refuse (although most states permit parents this right, 
specifically on religious grounds).4 A recent statement of CORN, however, 
maintains that "most state screening programs use informed refusal." 34 
In Iowa the statutes governing newborn screening provide for what could 
be called "informed screening" but not for informed consent. The statute 
states: "Parents or guardians shall be informed of the type of specimen, how 
it is obtained, the nature of the diseases being screened, arid the consequences 
of treatment and nontreatment. Should a parent refuse the test, said refusal 
shall be documented in writing and will become a part of the medical rec-
ord."34 The main strength of the Iowa statute is that the parents are to be 
informed that a sample is to be taken and that the tests are to be conducted. 
But while the statute requires written documentation of parental refusal (the 
grounds for which are not specified), it does not specifically require consent 
or written documentation of consent. Furthermore, while the content of the 
information provided to parents is relatively comprehensive (including the 
consequences of treatment and nontreatment), the language of the statute ad~ 
dresses issues related to metabolic screens. The law clearly does not under-
stand this information according to the paradigm of "genetic" information; it 
does not apprise the parents of the types of collateral information that might 
be obtained from a genetic test or therefore of the risks and benefits of the test 
itself. 
Although controversy still exists, consensus is shifting toward agreement 
that newborn screening ought to be understood under a model of genetic 
information and that, at the least, it ought to be governed by standard canons 
of informed consent. The Committee on Assessing Genetic Risks of the Insti-
tute of Medicine recommended that "informed consent should also be an 
integral part of newborn screening, including disclosure of the benefits and 
risks of the tests and treatments."32 Likewise, the proposed Genetic Privacy 
Act (see below) would require written parental authorization before obtaining 
a sample for testing.35 Some persons believe, however, that the costs of obtain-
ing (in terms of the time of the practitioner) and of documenting such con-
sent would be prohibitive.36 Additionally, such information, even if properly 
communicated to parents, might discourage them from consenting. States 
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would have to weigh the value of the practice of parental consent against the 
low risk that the child will suffer from one of the diseases tested for. N everthe-
less, given the changing nature of the information being obtained through 
newborn screening and the evolution in current understandings of informed 
consent in medicine, it will be increasingly difficult to justify conducting new-
born screening in the absence of informed consent. The content of such con-
sent is a separate matter and is addressed below. 
NEWBORN SCREENING FILTER CARDS AS DNA DATABANKS: 
ETHICAL CONCERNS SURROUNDING SECONDARY USES 
Until technological advances are made, many of the issues surrounding the 
use of DNA-based assays in newborn screening programs will remain hypo-
thetical; it is prudent, however, to think them through carefully and shape 
provisional policies in advance of exigency. A second set of issues is, however, 
upon us: issues related to DNA databanking and secondary use of newborn 
screening samples. Recently, the general issue of DNA databanking and sec-
ondary use of biological samples has received significant attention. A review 
of this discussion is necessary to set the context for consideration of the ethical 
issues surrounding newborn screening filter cards as DNA databanks. 
DNA Databanking: An Overview 
The American Society of Human Genetics (ASHG) outlined points to con-
sider regarding DNA banking and analysis as early as 1987.37 Philip Reilly ini-
tiated discussion of newborn screening filter cards as a form of DNA data-
banking in 1992'" 8 In 1995 DNA databanking was addressed in four separate 
settings: the American College of Medical Genetics (ACMG),38 a workshop 
held under the aegis of the National Center for Human Genome Research 
(NCHGR),39 a working group under the aegis of the National Institutes of 
Health/ethical, legal, and social implications (of genome research) (NIH/ 
ELSI) program that drafted the Genetic Privacy and Nondiscrimination Act,19 
and a study of informed consent in genetic research conducted by Robert 
Weir and Jay Horton at the University of Iowa.40 
DNA databanks can be comprised of samples gathered in different con-
texts. Reilly identifies at least six: (1) academically based repositories of scien-
tists who are studying one or more genetic disorders; (2) commercially based 
repositories that offer DNA banking as a service to researchers and individuals 
who may have some reason to store their DNA; (3) state-based DNA forensic 
banks; (4) DNA banking by the military to assist in the identification ofhu-
man remains; (5) specimens obtained for clinical diagnosis and then retained; 
and (6) newborn screening cards.9.8,28 
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The extent to which newborn screening programs have become de facto 
or "inchoate" DNA databanks is unclear. McEwen and Reilly, in a study 
published in 1994, noted that currently forty (or 75 percent) of the newborn 
screening programs in the United States retain the blood -spot filter cards from 
one year to indefinitely.8 CORN, however, maintains that only eighteen states 
retain their cards for more than one year, stating that "most newborn screen-
ing programs destroy all residual DBS samples within a year after the newborn 
screening analytical process has been completed." 33 McEwen and Reilly fur-
ther note that most who retain these cards have begun doing so recently and 
that there is a trend nationally toward retaining them and toward retaining 
them for longer periods as their value as a databank is increasingly recognized. 
CORN concurs with this latter point. 
Samples collected in newborn screening labs, as well in other repositories, 
can be used for four types of secondary purposes: forensics, diagnostics, re-
search, or the development of commercial products. They can be used for 
these secondary purposes in two forms, either retaining identifying linkages 
to the original source or in an "anonymized" fashion . Finally, a distinction is 
generally made between biologic samples that have already been collected (i.e., 
existing repositories) and the collection of samples in the future. 
Consideration of issues surrounding secondary uses of newborn screening 
samples returns us to the issue of informed consent raised earlier. The rec-
ommendations of the ACMG mentioned earlier, the NCHGR Workshop on 
Genetic Research on Stored Tissue Samples, the Genetic Privacy Act, and the 
Weir/Horton study pertain almost exclusively to issues of informed consent. 
While a detailed account of these recommendations is beyond the scope of 
this essay, a brief summary will provide a context for thinking through issues 
of consent for newborn screening. 
In specifying the content of the information that ideally ought to be com-
municated to patients/research participants who become the source of the 
genetic material collected in these databanks, the four sets of guidelines and 
recommendations recognize the importance of the traditional, central ele-
ment of informed consent: in order to protect the research participant's au-
tonomy and to minimize harm, participants must be apprised of the nature 
of the project and the possible risks and benefits that might accrue to them 
through participation; they can authentically choose to undertake certain 
courses of action if they value the end sufficiently to deem the risks worth 
taking. In addition, these four proposals expand on this traditional under-
standing to encompass a more substantive understanding of the relationship 
between the patient/participant and the investigator. They attend seriously to 
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the participants' contribution to the research endeavor, almost locating partic-
ipants as equal partners with investigators. 
Generally, these four sets of recommendations treat the use of identifiable 
or linkable samples and anonymized samples separately. Given their slightly 
different foci, not all of these four documents highlight the same concerns. 
However, broad areas of agreement can be identified. With regard to identifi-
able or linkable samples to be collected in the future, these findings recom-
mend that fully informed consent, governed by well-established canons for 
both the practice of medicine and research involving human subjects, should 
be obtained. They recommend that patients/research participants should re-
ceive standard information regarding (l)} he original purpose, risks, and bene-
fits of the clinical test or research project; (2) retention of the sample, includ-
ing location and conditions under which it will be retained; (3) possible 
secondary uses of the sample; and (4) possible ramifications for the individual 
of secondary uses. The patients/participants ought then be accorded the rights 
to consent and determination corresponding to these areas. 
These recommendations also take up the issue of how to treat identifiable 
samples that have already been collected, already reposing in databanks, for 
which the sources may not have been thoroughly informed when they gave 
their original consent. How ought one then proceed? For research proposing 
to use these in an identifiable manner, three options have been presented. 
First, if possible, the source of the identifiable sample should simply be recon-
tacted and give consent for the further use. Objections were raised, particu-
larly in the NCHGR document, that this would be impracticable and would 
prove prohibitive to investigators.39 Consequently, a second course of action 
proposed that the investigator and the IRB should revisit the consent docu-
ment of the person who provided the sample to determine whether, in that 
context, he or she had agreed to the use of the sample for genetic research. 
The workshop concluded that, while it would probably be difficult to infer 
consent from most informed consent documents (given their general inade-
quacy), this would be a valid course of action; if it was successful, further 
consent would not be necessary. Finally, following federal regulations, if the 
research involves no more than minimal risk, and the investigator can dem-
onstrate that reconsenting the participants would be prohibitively burden-
some, members of the workshop agreed that consent might be limited or 
waived in some circumstances.4o 
Finally, in general, these four sets of recommendations say very little about 
the use of anonymous or anonymized samples (the NCHGR statement provides 
the most extensive discussion); for the most part, they simply presume the 
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propriety of the use of anonymized samples for secondary purposes. This ac-
cords with the recommendations of both the NIH Office of Protection from 
Research Risks (OPRR) and the Committee on Assessing Genetic Risks of the 
Institute of Medicine, who endorsed the use of anonymous stored samples for 
genetic research.32. 41 This is also in keeping with the federal regulations which 
exempt from the requirements for protection of human participants the use 
of existing specimens "if the information is recorded by the investigator in 
such a manner that subjects cannot be identified, directly, or through identi-
fiers linked to the subjects." 42. 39 
This high degree of consensus, however, does not mean that the issue of 
the use of anonymized samples is settled. Some members of the NCHGR 
Workshop suggested, for example, that anonymizing an existing identifiable 
sample without seeking consent for the specific seconda;y research project 
or other use is problematic, insofar as the researchers had an opportunity to 
obtain consent but did not pursue it.39 Others ques~on whether biological 
samples can truly be anonymized, especially given the increasing power of 
computers to store data, network, and search multiple databases." Members 
of the NCHGR Workshop defined a sample as anonymous "if and only if it is 
impossible under any circumstances to identify the original source." They 
concluded that this is more possible with data sets involving large population 
groups (even when certain demographic or clinical information is retained), 
but questioned whether this was truly possible for a small group of samples 
(e.g., from the laboratory of an individual researcher).39 Ellen Wright Clayton 
further suggests that even the process outlined in the Genetic Privacy Act 
(GPA) for ensuring unlinkability is inadequate.44 
But even if one could guarantee that the sample could not be linked back 
to its source, Clayton further argues that using anonymized samples is not 
simply nonproblematic.44 Arguments for the use of anonymized samples are 
premised primarily on the concept of benefit versus harm. Through the use 
of anonymized samples, advocates argue, benefits can accrue to the public 
good through the acquisition of knowledge and the development of useful 
therapies. At the same time, since the samples are anonymous, no harm can 
come, via the research, to the individuals who donated the samples. Clayton 
maintains, however, that the use of anonymous samples without the partici-
pants' consents (which would pertain to the use of samples in existing reposi-
tories) or the open-ended blanket consent for the use of anonymized samples 
could harm participants in two ways. First, broadening the more traditional 
notion of informed consent (as mentioned above), Clayton suggests that 
samples that are anonymized could be used for research that could stigmatize 
or harm the particular demographic group to which the individual belongs 
20 : Clinical and Research Settings 
(e.g., women, African Americans); harm could thereby come to the indi-
vidual. Second, taking a more substantive view of the participants' involve-
ment in the research endeavor, Clayton argues that the use of anonymized 
samples could harm the participants' interests by potentially involving them 
in research that they would find objectionable (e.g., certain sorts of behavioral 
research) even if it did not harm them directly; such research would make 
them collaborators in a project that they would find offensive or antithetical 
to their values, commitments, and understanding of the common good. 
To address this issue, Clayton recommends that research protocols using 
anonymized samples not be exempt from IRE review and that in their risk/ 
benefit calculations IRBs consider not only harm to the individual participant 
but the larger possibility of harm to society or to particular groups within 
society. She also concurs with the recommendations outlined in these various 
documents that patients/participants be given the ability, as part of the con-
sent process, to determine whether their samples will be retained in an iden-
tifiable or anonymized fashion and be apprised that their samples might pos-
sibly be used for research. Philip Reilly, on the contrary, strongly objects to 
the suggestion that individuals might be permitted to prohibit anonymous use 
of their samples. Arguing that this would alter a long-standing practice in 
medical research, he believes it would be unnecessary "and possibly socially 
harmful," by prohibitively increasing the expense of valuable research in order 
to "only abstractly protect individual autonomy." 36 
Council of Regional Networks for Genetic Services' "Guidelines" 
In 1996 CORN issued a statement entitled "Guidelines for the Retention, 
Storage, and Use of Residual Dried Blood Spot Samples after Newborn 
Screening Analysis." 33 They report that currently most states have few or no 
procedures for retaining, storing, or retrieving and most programs have no 
laws or regulations governing the use of what they term "residual DBSs (dried 
blood spots)." CORN strongly recommends that each newborn screening 
program begin by developing a sound justification for either saving or discard-
ing DBSs after analysis is complete; this justification ought to be based on 
anticipated secondary uses of DBSs, the public health goals of the newborn 
screening program, and sound scientific data about long-term storage and 
analyte stability. If a program decides to retain its DBSs, it should develop 
duration parameters, storage guidelines, and retrieval procedures (including 
extensive documentation systems) consistent with the uses articulated in its 
justification. Finally, they recommend that each organization establish a re-
view process, a method for prioritizing and agreeing to requests, and a written 
policy to govern release of DBSs. 
Anonymized Newborn Screening Cards : 21 
The guidelines articulate the importance of informed consent, noting that 
with current consent practices issues of ownership and secondary use remain 
unresolved and need to be clarified. In general, though, they say little about 
what information that consent ought to contain, with one exception: "The 
collection form and educational material for parents could indicate that the 
sample becomes the property of the state and that, unless the parents object 
in writing, the sample may be used without personal identifiers in studies 
related to preventing birth defects and disorders of the newborn or for pro-
tecting public health." 33 They are, however, explicit about the parameters 
which should govern release. First, as noted above, each request for release 
of DBSs should be subject to a review process within the agency. In addition, 
for all proposals (except for internal anonymous research uses), whether the 
samples are identifiable or anonymized, they recommend r~view and approval 
by "a Human Subjects Review process." They articulate one primary criterion 
that should guide the internal review, namely, that s~condary uses of DBSs 
should contribute to the primary goals of newborn screening - public health 
or family health. CORN seems equally open to the use of anonymized and 
identifiable samples. The guidelines note that anonymized samples negate 
the need for parental consent, although they do recognize Clayton's concerns. 
The release of identifiable samples, however, or of identifying information, 
requires a signed parental consent, and they state that a protocol for obtain-
ing parental consent needs to be developed. If implemented, these guidelines 
would result in elaborate documentation and retrieval systems aimed at en-
suring privacy and confidentiality. 
N E WBORN SCRE ENING BLOOD-SPOT FILTER C ARDS 
AS DNA DATABANKS 
Given these findings concerning DNA databanks in general and the reten-
tion, storage, and use of newborn screening samples, what factors ought to 
guide newborn screening programs as they consider whether or not their fa-
cilities will retain samples and indeed establish a DNA databank and as they 
evaluate individual requests for secondary release of these samples? Three fac-
tors are primary: informed consent, goal of the secondary use, and review 
process. A framework based on these factors should be helpful in addressing 
the different issues presented by research, legal/forensic, diagnostic, and com-
mercial requests for these samples. 
Before considering issues particular to different secondary uses, serious at-
tention needs to be given to the process and content of informed consent in 
the current practice of newborn screening. This reflects in part the evolving 
understanding of informed consent within the scientific, legal, and ethical 
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community. But more importantly, the trend toward seeing newborn screen-
ing labs as DNA databanks which can provide samples for secondary purposes 
has fundamentally altered the nature or status of the blood-spot filter card. 
Previously, one could have argued that newborn screening was simply one of 
a series of diagnostic assays performed under the umbrella of general parental 
consent to actions promoting neonatal health. But now the blood-spot filter 
card has become a commodity, an item with "value," to be used for purposes 
unrelated to the health of the individual newborn. In this new context, it will 
be increasingly difficult to justify conducting newborn screening in the ab-
sence of informed consent. 
What information ought to be included in this informed consent process? 
We find that most of the items specified by the ACMG, the NCHGR, the GPA, 
and Weir/Horton regarding informed consent for DNA banking in general 
are strongly supported with regard to newborn screening. Clearly, the infor-
mation about the primary purpose, risks, and benefits of the tests themselves is 
required and should be explained thoroughly to parents. Furthermore, states 
would have to offer compelling justifications for not including information 
on retention, possible secondary uses, and access to subsequent information. 
Once state newborn screening programs develop protocols governing reten-
tion, storage, and use of residual DBSs, this information should be easy to 
convey to parents. 
Until issues of ownership are clarified, some areas will remain contentious. 
As noted above, the CORN guidelines suggest, without discussion and con-
trary to others' recommendations, 19. 40 that newborn screening samples should 
become the property of the state. If so, at what point would these ownership 
rights be established? How would this affect parents' abilities to make initial 
specifications about the disposition of their child's sample? Would parents 
be able to specify that the sample should be destroyed rather than retained? 
Would they be able to do so at a later date? Would they be able to specify 
which secondary uses they would permit and which they find objectionable? 
Would they be able to specify whether the sample ought to be anonymized or 
remain identifiable? Would they be able to specify which investigator or insti-
tution may have access to their child's sample? Are there analogies for such 
transfer of ownership to the state, in total, in the areas of public health and 
medicine, and, if so, what are the limits of these analogies with regard to new-
born screening? 
Much more work needs to be done with regard to these issues of owner-
ship. In the meantime, restrictions of parental authority in these areas would 
make secondary uses of newborn screening samples much more difficult to 
justify. We suggest that, in thinking through this relationship between parent, 
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child, and state, it might be more fruitful to use a different model for under-
standing newborn screening cards (or samples retained in most DNA data-
banks), seeing them not as commodities to be "owned" but rather as material 
held in "trust" by the state and the newborn screening laboratory for purposes 
of public health and for the interests of the individual contributor. This sug-
gests a fiduciary rather than a proprietary role for the state and the newborn 
screening laboratory. Insofar as the cards contain information about individ-
uals which can affect them materially, individuals should be able to retain 
some interests in and rights vis-a-vis the samples. They should be able to de-
cide whether their cards are to be retained or not, whether they can be used 
for secondary purposes, and, if so, what those purposes might be. At the same 
time, this model would suggest that newborn screening programs be under-
stood as foundations or trusts, managing a finite public resource with impli-
cations for the common good. Examining the issues of own~rship/stewardship 
as modeled by trusts and foundations in the United St'!.tes context might pro-
vide a useful, although imperfect, analogy. 
One distinctive characteristic of foundations or trusts is that they are gen-
erally circumscribed by specific goals which delimit the deployment of their 
resources. So likewise, we would like to suggest, are newborn screening pro-
grams. These programs, as mentioned above, have been established to pro-
mote two related goals: individual/family health and public health. Newborn 
screening programs exist, first, to protect and promote the health and well-
being of the individual newborn; this original purpose ought never be contra-
vened. Thus, uses that could bring risk to the individual newborns or their 
families, even if balanced by greater social goods, ought to be disallowed. The 
second goal, as noted by CORN, is the promotion of the goals of newborn 
screening and public health. Secondary uses that contribute to these goals, 
without compromising the well-being of the individual sources, ought to be 
permissible. 
How is it to be determined whether a particular request falls within the 
parameters circumscribed by these goals? Especially at this early juncture, each 
request should be evaluated on a case-by-case basis through a thorough, goal-
oriented review process. First, as CORN suggests, each newborn screening 
program should identify and articulate (in written form) what it understands 
to be its goals. Based on these, as CORN also recommends, each newborn 
screening program should develop a written protocol for the review of re-
quests for secondary release. This process should include review and approval 
by both the newborn screening lab and/or state oversight body and the inves-
tigator's local IRB. 
In conducting this review, the reviewers ought to look at three issues. The 
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first consideration would be whether proposed investigation directly fosters 
the purposes of newborn screening and public health, as discussed above. 
A second and related consideration would be the impact of the use of the 
samples and the research project's potential for harm to society as a whole or 
to a particular social group (the point raised early by Clayton). Insofar as 
newborn screening programs are guided by public health considerations, new-
born screening programs must necessarily broaden the concept of "harm" 
from a narrowly individualized application; this broader vision makes consid-
eration of the impact of research on certain social groups an integral part of 
the evaluation process. Third, this review process ought to evaluate requests 
based on scientific and allocation criteria. The NCHGR, for example, suggests 
that, for both previously anonymized samples and samples which are to be 
anonymized, IRE review is appropriate and ought to consider five factors: 
(1) can the information be obtained any other way; (2) is the proposed inves-
tigation scientifically sound; (3) how difficult would it be to recontact subjects 
and obtain consent; (4) if the samples are finite, what impact will this have on 
the clinical needs of the patient and family; and (5) will the pursuit of anony-
mous research preclude the sources from obtaining effective medical inter-
ventions? 39 Thus, newborn screening cards ought not be used simply because 
they are available and expedient. Two issues must be taken into account re-
garding the use of these cards as a public resource. First, is the proposed use 
scientifically sound and is it reasonable to presume that useful information 
will be forthcoming? In other words, some clear "benefit" should be justifiably 
anticipated. Second, since the newborn screening databank is a public re-
source, one request should not deplete a particular sample or sample set. The 
newborn screening laboratory should only release part of the original sample 
(which CORN recommends) or should require that the secondary user make 
samples available to others. 
Given the relative novelty of the use of newborn screening cards for sec-
ondary purposes, the concerns that surround them, the dubious consent con-
ditions under which many currently retained samples were obtained, and the 
dearth of protocols within newborn screening laboratories concerning their 
use, it would be reasonable to recommend that for a certain defined period 
all proposals utilizing newborn screening cards (both identifiable and anony-
mized) be thoroughly reviewed by institutional IREs as well as the appropriate 
state agencies responsible for newborn screening. At the end of this period, 
these protocols could be retrospectively reviewed, problems identified, con-
cerns allayed, and guidelines established. We suggest that this would be a cau-
tious yet constructive way to proceed. 
This framework, then, should be able to provide guidance for the spectrum 
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of secondary uses for which newborn screening cards might be requested: 
research, legal (or forensic), diagnostic, or commercial. First, research con-
ducted utilizing newborn screening cards could contribute to the goals of 
newborn screening and public health. At this juncture, it is difficult to imagine 
research scenarios which would require identifiable samples. Thus, we suggest 
that only anonymized samples be released for research, unless a compelling 
case can be made by the investigator and specific consent is obtained from 
the parents and/or source. This accords with the recommendations of the 
Committee on Assessing Genetic Risks. 32 Implementation of a review process, 
such as that outlined above, should ameliorate concerns about the use of pre-
viously obtained anonymized samples. Samples obtained in the future should 
carry with them permission to be enrolled in research in an anonymized fash-
ion. If samples are to be released with identifying informa~ion attached, par-
ents should be recontacted for consent. This step would also partially amelio-
rate concerns regarding the lack of original consent !"ith previously stored 
samples. To reiterate CORN's recommendations, each agency needs to de-
velop very carefully justified and written procedures for retention, storage, 
use, and processing of newborn screening cards and once armed with these 
procedures should still proceed very cautiously. In developing these proce-
dures, great care will need to be taken with regard to the protections of con-
fidentiality and privacy, given the public nature of the databank. 
Second, release of newborn screening cards for legal or forensic purposes 
would be justifiable only on a more limited basis. Clearly, these samples would 
need to be released in an identifiable form; the use of large quantities of 
anonymized newborn screening samples to gather data on genetic variations 
within a population would not, for example, be justified given that this par-
ticular application does not fall under the aegis of the goals of newborn 
screening or public health. With regard to individual situations, the CORN 
guidelines maintain (although they do not discuss) that samples should be 
released in legal cases only "after careful consideration" and consultation with 
legal counsel. CORN does provide examples of compelling circumstances in 
which such use might be appropriate, primarily for determination of a previ-
ously unknown cause of death of the newborn from which the sample was 
obtained. Beyond issues of benefit to an individual or family of an individual 
source, or the determination of issues of negligence against a laboratory, it 
would be difficult to justify legal uses of newborn screening samples within a 
public health framework. 
Ought newborn screening samples be used for secondary diagnostic pur-
poses? Again, the range of justifiable situations in which this might be appro-
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priate is more limited. For if, for example, the source of the individual sample 
is alive, diagnostic tests could be conducted on fresh samples taken within 
explicitly medical settings, where proper informed consent and counseling 
could be provided. This would be more appropriate. The use of these samples 
for diagnosis of later-onset conditions, should new diagnostic tests be devel-
oped, would not, per our discussion above, be appropriate within a newborn 
screening context. Again, in the case of a deceased child, retained newborn 
screening samples might be able to provide useful information to families re-
garding diagnosis of siblings, linkage studies, or subsequent decisions about 
pregnancies. Release for diagnostic use in these settings could be justified under 
a broad understanding of "benefit to the newborn," if one perceives a child and 
his or her interests as being intimately connected with those within the family 
network. Release in these circumstances would require parental consent, and 
issues of confidentiality and privacy would need to be well protected. 
Finally, ought newborn screening cards be released to commercial entities 
for the purpose of developing proprietary products or services? This is an area 
which has received the least attention with regard to DNA databanking over-
all and newborn screening in particular. The CORN guidelines allude briefly 
to the possibility of commercial requests, noting only that "reimbursement 
should also be considered for provision ofDBSs to commercial manufacturers 
for research applications." The premise of this position is that commercial 
ventures can help offset the costs associated with the storage and retrieval of 
the newborn screening cards. Within the framework that we have developed, 
release for commercial use could be justified only in the context of an inves-
tigation explicitly designed to benefit public health, particularly the goals of 
newborn screening (i.e., diagnosis of conditions for which treatment is avail-
able and for which immediate intervention will make a difference) . Beyond 
this, it is difficult to imagine plausible scenarios. In addition, the possibility 
of commercial release again raises issues of ownership and profit-sharing. 
Clearly, it is not unreasonable to suggest that ownership rights in the samples 
ought not be transferred to commercial interests and that a percentage of the 
profits from a commercial venture should devolve to the newborn screening 
program for the benefit of public interests (cognitive of the issue of conflict-
of-interest that this might raise) . 
If such release is approved, ought the samples be released in an identifiable 
or anonymized form? Straightforward anonymizing of the samples provides 
the strongest safeguards on privacy and confidentiality but eliminates the pos-
sibility of profit-sharing with the individual sources. An alternative might be 
to reobtain the consent of those whose samples are to be used and then to 
Anonymized Newborn Screening Cards : 27 
release them in an anonymized fashion, a percentage of the profits then de-
volving equally to all who participated in the study. Clearly, this issue needs 
further study. 
Conclusion 
This study illustrates a relatively easy and efficient method for conducting 
DNA-based analyses on large numbers of samples derived from blood-spot 
filter cards. This method, when used on samples from the INMSP, could be 
used to determine allele- or carrier-frequencies within the Iowa population. 
This would provide a means of identifying additional types of genetic disor-
ders that affect Iowa newborns and could thereby provide useful data to in-
form legislative or other public decisionmaking regarding public health policy 
and expenditures. 
With further refinements, this approach could feasibly be used to develop 
DNA-based analyses for newborn screening programs. Such an application is 
not recommended at this time. Although technical issues concerning diagnos-
tic efficacy could be resolved, and although DNA-based analyses would re-
solve certain problems like early discharge of newborns, DNA-based assays 
also introduce the issue of collateral information, and they pose real risks to 
newborns and their families. Until guidelines or legislation are implemented 
that will minimize those risks, current methodologies will remain more ap- . 
propriate and cost-effective. We further hold that if DNA-based assays are 
introduced into newborn screening, the scope of application should be limited 
to the diagnosis of diseases in newborns for which treatment is available and 
for which immediate intervention makes a difference in morbidity or mor-
tality. Testing for presymptomatic conditions, susceptibility, or carrier status 
is not appropriate within the parameters of newborn screening. 
Finally, we recommend that well-established standards for obtaining in-
formed consent from parents for newborn screening be implemented wher-
ever newborn screening is conducted, especially in light of the developing 
trend toward seeing repositories of newborn screening samples stored in state 
facilities as DNA databanks amenable to secondary uses. With regard to sec-
ondary use of newborn screening samples, appropriate informed consent 
ought to be obtained for these uses. We recommend that prior to the release 
of newborn screening samples for secondary purposes state newborn screen-
ing labs, in conjunction with CORN, develop thorough written guidelines and 
procedures to govern retention, storage, and release, and institute substantive 
review processes to determine which instances of secondary use correspond 
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with the goals and responsibilities of newborn screening programs. In light of 
this, we suggest that both identifiable and anonymized samples can be used in 
the context of research, with appropriate protections. Further study needs to 
be done regarding legal and commercial applications. Overall, it remains a 
question of how to balance legitimate interests and goals of research that con-
tributes to the common good while protecting the well-being and interests of 
those newborns who contribute to the research endeavor. 
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